5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

Bibliographic Details
Main Authors:	J. Gligorov, X. Pivot, B. Ataseven, M. De Laurentiis, A. Llombart, K.H. Jung, A. Manikhas, H.A. Azim, A. Alexandrou, K. Gupta, L. Herraez-Baranda, N. Tosti, E. Restuccia
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621000977

Internet